Depression, Anxiety Clinical Trial
Official title:
Assessing the Cognitive Effects of Chronic Benzodiazepine Use in Patients: A Comprehensive Study Using fNIRs and PET/MRI Technologies
This study explores the impact of long-term benzodiazepine (BZDs) use on cognitive function and associated neuroimaging markers. While BZDs are established treatments for conditions like anxiety and insomnia, recent warnings highlight risks, including neurocognitive effects. Neuroimaging studies indicate potential neuroprotective effects of BZDs. Functional near-infrared spectroscopy (fNIRS) measures cerebral cortex function during cognitive tasks. Combining fNIRS with mood and cognitive scales, this study assesses cortical activation. 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) evaluates brain metabolism. DPA-714 PET assesses neuroinflammation. The primary objective is to compare brain functional activation, metabolism, and neuroinflammatory levels between long-term BZD users and non-users. This comprehensive approach aims to provide insights into BZD effects on cognition and associated brain markers.
Benzodiazepines(BZDs) have been long-established treatments for various conditions, including anxiety disorders and insomnia. Recent FDA warnings emphasize the risks of misuse and dependence associated with BZDs. Epidemiological investigations have consistently raised concerns regarding the long-term utilization of GABAergic medications, such as BZD and Z-drugs, due to their observed association with an elevated likelihood of neurocognitive impairments, including the development of Alzheimer's disease(AD). Recent neuroimaging studies have provided insights into the neuroprotective effects of BZD. These studies reveal that prolonged use of BZD in humans is associated with reduced amyloid deposition and a greater hippocampus volume. Functional near-infrared spectroscopic imaging utilizes changes in measured near-infrared light to monitor relative changes in oxyhemoglobin and deoxyhemoglobin concentrations in the cerebral cortex, allowing the detection of dynamic changes in cerebral cortical function during cognitive processing states. In this study, investigators will use functional near-infrared spectroscopy (fNIRS) to measure oxygenated (HbO2), deoxygenated hemoglobin (HbR), and total hemoglobin activation in various parts of the cortex, combined with mood and cognitive scales. Brain metabolism, measured using 2-deoxy-2-fluoro-D-glucose-positron emission tomography (FDG-PET) imaging, can guide clinicians in both research and clinical evaluation, with specific patterns of brain metabolism reduction aiding in the diagnosis of AD or related disorders. The PET tracer DPA-714, binding to the 18 kDa translocator protein (TSPO), provides a non-invasive measure of neuroinflammation in activated microglia/macrophages within the mitochondria. The primary objective of this study is to observe differences in brain functional activation, brain metabolism, and brain neuroinflammatory levels between subjects on long-term BZDs use and those not taking BZDs. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04122482 -
An Online Course for Improving Knowledge and Access to Mental Health Accommodations in Canadian Enterprises
|
N/A | |
| Completed |
NCT04085861 -
Mental Health in Dancers; an Intervention Study
|
N/A | |
| Recruiting |
NCT06060210 -
Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion
|
Phase 4 | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Recruiting |
NCT06065787 -
NeuroGlove Anxiety and Depression Study
|
N/A | |
| Active, not recruiting |
NCT04583891 -
Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design
|
N/A | |
| Completed |
NCT05554042 -
Kintsugi Voice Device Study
|
||
| Not yet recruiting |
NCT06162624 -
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
|
N/A | |
| Completed |
NCT02954250 -
Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide
|
Early Phase 1 | |
| Recruiting |
NCT05647499 -
Evaluating the Back 2 School Program in a Norwegian Setting: A Multicenter Pilot Study
|
N/A | |
| Completed |
NCT03980873 -
Cognitive-Behavioral Therapy for Young Adult Lesbian, Gay and Bisexual: Transdiagnostic Minority Stress Approach
|
N/A | |
| Completed |
NCT04422327 -
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
|
Phase 1/Phase 2 | |
| Completed |
NCT05368155 -
Chronic Pelvic Pain and Education Skills Training for Women Veterans
|
N/A | |
| Completed |
NCT05455905 -
Voice Biomarkers Predictive of Depression and Anxiety
|
||
| Completed |
NCT03272516 -
Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients
|
N/A | |
| Not yet recruiting |
NCT06027047 -
Breakthrough Anxiety and Sleep Evaluation Using Linked Devices and Smartphone Application Onar (BASEL)
|
||
| Not yet recruiting |
NCT05535101 -
Non-invasive Brain Stimulation in Patients With Methamphetamine Use Disorder
|
N/A | |
| Recruiting |
NCT04418115 -
Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?
|
N/A | |
| Completed |
NCT04905524 -
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
|
N/A | |
| Recruiting |
NCT03953118 -
Azithromycin for Meibomian Gland Disease
|
Phase 4 |